The Pfizer partnership validates Novavax's Matrix-M technology and provides significant future revenue potential. Traders should monitor milestone achievements and royalty streams. The strong revenue growth and improved profitability suggest a turnaround, but the decline in Nuvaxovid sales and cash balance warrant caution. The $330 million credit facility strengthens the balance sheet for future R&D investments.
How the stock moved after the report
BULLISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Feb 26 $11.19entry
- T+1 · 9mo ago −9.38%α −8.93% · $10.14
- T+5 · 9mo ago −10.72%α −9.60% · $9.99
- T+20 · 8mo ago −20.02%α −13.62% · $8.95
- T+60 · 6mo ago −19.75%α −27.50% · $8.98
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Novavax reported strong financial results for Q4 and full year 2025, with revenue up 67% YoY to $147 million in Q4 and $1.12 billion for the full year, driven by Sanofi milestones and licensing revenue. The company also announced a major non-exclusive license agreement with Pfizer for its Matrix-M adjuvant technology, receiving a $30 million upfront payment and potential for up to $500 million in milestones. Despite a cash balance decline to $751 million, Novavax secured a $330 million credit facility and guided to $230-$270 million in adjusted revenue for 2026.
Key Financial Metrics
Key Facts
- Q4 2025 revenue: $147 million (+67% YoY)
- Full year 2025 revenue: $1.123 billion (+65% YoY)
- Net income: $18 million in Q4 2025 vs. $81 million loss in Q4 2024
- Pfizer agreement: $30 million upfront, up to $500 million in milestones, and high-mid-single digit royalties
- Sanofi partnership: $225 million in milestones earned in 2025
- Cash balance: $751 million as of Dec 31, 2025
- 2026 revenue guidance: $230-$270 million (adjusted total revenue)
Financial Impact
Revenue increased by $589 million YoY to $1.123 billion in 2025, with Q4 revenue up $59 million to $147 million. Net income improved by $99 million YoY in Q4.
Segment Breakdown
| Segment | Revenue | Growth |
|---|---|---|
| Nuvaxovid Sales | $625.0M | Not reported |
| Sanofi | $386.0M | -16.0% |
| Licensing, Royalties and Other Revenue | $438.4M | -7.0% |
Risk Factors
- Decline in Nuvaxovid product sales from $625 million in 2025 to $35-$45 million expected in 2026
- Cash balance decreased from $938 million in 2024 to $751 million in 2025
- Future revenue dependent on partner performance (Sanofi, Pfizer) and milestone achievement
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001000694-26-000011 |
| Document: nvax-20260226.htm | 0001000694-26-000011 |
| Document: 0001000694-26-000011-index-headers.html | 0001000694-26-000011 |
| Document: 0001000694-26-000011-index.html | 0001000694-26-000011 |
| Document: 0001000694-26-000011.txt | 0001000694-26-000011 |
Track record
9 reports on NVAX
2 of 3 bullish or bearish reports moved the stock their way by T+5. Best: +25.51% at T+20 after the Oct 16, 2026 report. 3 of 3 went positive at some point.
Filters
- Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $10.20 Now $8.06 −20.98% settles Nov 17
- Nov 5, 202611d ago 8-K Bullish 6/10 Entry $9.78 to $8.76 Now $8.06 −17.59% ▼ −10.43% −13.72% vs SPY
- Oct 29, 202618d ago 8-K Bullish 5/10 Entry $10.08 to $10.78 Now $8.06 −20.04% ▲ +6.94% +9.65% vs SPY
- Oct 16, 20264w ago SC 13G Neutral 4/10 Entry $10.82 to $9.40 Now $8.06 −25.51% ▼ −13.12% −12.98% vs SPY
- Oct 16, 20264w ago SC 13D/A Bearish 6/10 Entry $10.82 to $9.40 Now $8.06 +25.51% ▲ +13.12% +12.98% vs SPY
- Aug 6, 202614w ago 8-K Neutral 5/10 Entry $7.74 to $8.14 Now $8.06 +4.13% ▲ +5.17% +3.96% vs SPY
- May 6, 202627w ago 8-K Neutral 4/10 Entry $9.36 to $9.62 Now $8.06 −13.89% ▲ +2.78% +1.65% vs SPY
- Apr 27, 202629w ago DEFA14A Neutral 2/10 Entry $8.07 to $8.03 Now $8.06 −0.12% ▼ −0.50% −0.90% vs SPY
- Feb 26, 202637w ago 8-K Bullish 8/10 Viewing Entry $11.19 to $9.99 Now $8.06 −27.97% ▼ −10.72% −9.60% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers